Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines.
COVID-19
SARS-CoV-2
delta
immunity
omicron
vaccines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
15 Dec 2022
15 Dec 2022
Historique:
received:
16
11
2022
revised:
10
12
2022
accepted:
11
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Around the world, rollout of COVID-19 vaccines has been used as a strategy to end COVID-19-related restrictions and the pandemic. Several COVID-19 vaccine platforms have successfully protected against severe SARS-CoV-2 infection and subsequent deaths. Here, we compared humoral and cellular immunity in response to either infection or vaccination. We examined SARS-CoV-2 spike-specific immune responses from Pfizer/BioNTech BNT162b2, Moderna mRNA-1273, Janssen Ad26.COV2.S, and SARS-CoV-2 infection approximately 4 months post-exposure or vaccination. We found that these three vaccines all generate relatively similar immune responses and elicit a stronger response than natural infection. However, antibody responses to recent viral variants are diminished across all groups. The similarity of immune responses from the three vaccines studied here is an important finding in maximizing global protection as vaccination campaigns continue.
Identifiants
pubmed: 36560562
pii: vaccines10122152
doi: 10.3390/vaccines10122152
pmc: PMC9782527
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148574
Pays : United States
Organisme : NIH HHS
ID : AI148574
Pays : United States
Références
Microbes Infect. 2022 Nov 15;25(1-2):105077
pubmed: 36400331
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062724
Immunol Rev. 2022 Sep;310(1):27-46
pubmed: 35733376
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Biomedicines. 2022 Sep 26;10(10):
pubmed: 36289664
Vaccines (Basel). 2022 Jul 29;10(8):
pubmed: 36016097
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
New Microbes New Infect. 2022 Jul;48:101021
pubmed: 36060548
Immunity. 2021 Aug 10;54(8):1652-1664
pubmed: 34380063
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
N Engl J Med. 2022 Mar 3;386(9):847-860
pubmed: 35139271
NPJ Vaccines. 2022 Jul 6;7(1):77
pubmed: 35794181
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Hum Antibodies. 2020;28(4):287-297
pubmed: 32986664
J Infect. 2021 Mar;82(3):399-406
pubmed: 33589297
Glob Health Res Policy. 2022 Apr 29;7(1):12
pubmed: 35488305
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Pathogens. 2021 Jun 06;10(6):
pubmed: 34204122
Immunity. 2021 Dec 14;54(12):2893-2907.e5
pubmed: 34614412
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
J Infect Dis. 2022 Apr 1;225(7):1141-1150
pubmed: 34888672
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Sci Transl Med. 2022 Feb 09;14(631):eabi8961
pubmed: 34874183
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccines (Basel). 2022 Sep 01;10(9):
pubmed: 36146520